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Summary To assess the efficacy, tolerability and safety of Levetiracetam (LEV)
therapy, we identified 21 (15 male; 6 female) patients with a history of benign
epilepsy with centrotemporal spikes (BECTS), with and without secondarily general-
ization in children and adolescents aged between 5.0 and 12.1 years. LEV was
administered as a first drug (number of patients = 9) or converted after previous
treatment with other AEDs (number of patients = 12). The patients were subdivided
into two groups: ‘‘newly diagnosed’’ patients and ‘‘converted’’ patients.
Patients were followed up for 12 months and all patients were able to continue on
LEV treatment. At the end of follow-up (12 months), all patients were seizure free or
showed a reduction of seizures>50%. LEV dosage ranged from 1000 to 2500 mg/daily.
Overall, 100% of patients completed the 12 months study, without any important side
effect. Somnolence and irritability occurred in two (9.5%) patients.
Our results support findings that LEVmonotherapy is effective andwell tolerated in
children with BECTS. Prospective, large, long-term double-blind studies are needed to
confirm these findings.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Benign epilepsy with centrotemporal spikes (BECTS),
known as benign Rolandic epilepsy (BRE), is a benign* Corresponding author. Tel.: +39 0871358015;
fax: +39 0871574831.
E-mail address: averrott@unich.it (A. Verrotti).
1059-1311/$ — see front matter # 2006 British Epilepsy Association
doi:10.1016/j.seizure.2006.12.006partial idiopathic epilepsy, characterized by partial
motor seizures, usually brief and infrequent, with or
without generalization recurringmostly during sleep,
with onset during childhood. The patients have
absence of neurological and mental deficits,1
although some authors have suggested that part of
these patients can show intellectual impairments.2
The EEG criteria are: normal background activity and. Published by Elsevier Ltd. All rights reserved.
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trotemporal spikes (CTS), increasing in frequency
during sleep.3,4 This type of epilepsy generally tends
to follow a benign course and the treatment is often
not required. However, treatment decision requires
clinical judgmentandobservationsover time. In fact,
treatment is started in subjects with frequent sei-
zures and/or seizures that recur during wakefulness,
or when the ictal events are disruptive to the patient
or family.5,6 Once assumed the treatment option, it
may be suitable to choose the best tolerated anti-
epileptic drug (AED), possibly at the minimal effec-
tive dosage.Valproic acid andCarbamazepine are the
most frequently prescribed AED in this type of epi-
lepsy.1,5
More recently, based on the particularly favour-
able pharmacokinetic profile and the good toler-
ability, Levetiracetam (LEV) has been successfully
considered as monotherapy option; the pharma-
cokinetic profile of LEV makes this AED a good
option for the treatment of pediatric patients.7
LEV is a novel AED which has been approved as
adjunctive treatment for adults with partial onset
seizures. Its mechanisms of action appear differ-
ent from other AEDs.8 LEV binds to a specific
membrane-binding site in the brain.9 It neither
affects glutamate or gamma aminobutyric acid-
mediated synaptic transmission,10,11 nor does it
modulate voltage dependent sodium or T-type
calcium currents.12 LEV is well tolerated and its
effectiveness was established in multicenter, well-
controlled pivotal trials.13—15 The safety profile is
consistent with that observed in many epilepsy
trials.16—18 Moreover, LEV has proven efficacy in
the treatment of partial seizures with or without
secondary generalization and refractory epilep-
sies;19—21 but preliminary observations are favour-
able for a broader use.
Therefore, LEV is widely used but the experience
in BECTS is limited, in fact, only Bello-Espinoza.22
have reported three cases of young children with
typical BECTS treated with LEV.
The objective of this study was to generate
information on LEV monotherapy in a group of chil-
dren and adolescents with BECTS.Patients and methods
Twenty-one subjects (15male; 6 female) with BECTS
were enrolled in this prospective study from five
centers of Italy. All patients have been diagnosed
with this type of epilepsy, according to the Inter-
national League Against Epilepsy (ILAE)3. The age of
seizures onset ranged from 5.0 to 12.1 years, with a
peak of frequency at mean  S.D. 7.7  4.4 years.All patients showed typical rolandic seizures. The
typical seizures were hemifacial, characterized by
clonic manifestations involving the hemiface, some-
times preceded by unilateral paresthesia involving
toungue, lips, gums and cheek; the jerks were often
associated with a lateral tonic deviation of the
mouth involving lips and toungue, and result drool-
ing due to sialorrhoea. The seizures lasted from less
than a minute to 3 min, and spreaded to the homo-
lateral arm and rarely to the leg. No permanent
deficits were observed in all cases.
Exclusion criteria were: neurological disorders or
intellectual impairment, history or presence of
pseudoseizures, history of recurrent psychotic or
major effective disorder, the use of CNS-influencing
medication, unless patients had been stabilized on
such medication for >1 months before the study,
metabolic disorders, active infection or neoplasm,
any clinically relevant progressive or serious illness
expected to interfere with the patient completing
the trial, previous treatment with LEV discontinued
due to adverse events.
In all cases, computed tomography or magnetic
resonance imaging before the trial confirmed the
absence of neoplasia or progressive cerebral or
neurodegenerative diseases.
In all patients, electroencephalograms (EEG)
were recorded during wakefulness with hyperventi-
lation and photic stimulation and during drowsiness
and sleep (stages 1—4); all patients show a normal,
well-organized and symmetrical background activ-
ity.We recorded only interictal EEGs: in all patients
we found typical CTS, clearly localized in the cen-
tral regions; the main spikes component was dipha-
sic with a maximum surface, negative, rounded
peak followed by a smaller positive peak; this was
followed by a negative or negative-positive slow
wave. A relatively minute positive spike often pre-
ceded this spike-slow wave complex. The spikes
significantly increased in frequency during drowsi-
ness and through all sleep stages.
LEV was administered as a first drug (number of
patients = 9) or converted after previous treatment
with other AEDs (number of patients = 12). There-
fore, the 21 patients were subdivided into two
groups: ‘‘newly diagnosed’’ (AED naı¨ve) group and
‘‘converted’’ group. In this second group of
patients, different AEDs were tried before introdu-
cing TPM treatment: Valproate (4 patients), Carba-
mazepine (6 patients), Oxcarbazepine (1 patient),
Lamotrigine (1 patient). All patients received these
AEDs monotherapy. In these 12 patients preexisting
AED treatment was gradually tapered during titra-
tion phase of LEV.
All patients began LEV 250 mg each evening and
dosing was escalated gradually; after titration, LEV
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dosages ranged from 1000 to 2500 mg/daily. All
patients were carefully followed at 6 and 12 months
after the beginning of LEV therapy. At each visit, the
investigator assessed the number and type of sei-
zures, adverse events, with their severity, relation-
ship to LEV treatment, and outcome. Each
treatment-emergent physical and neurological
abnormality was recorded as adverse event, as
was any condition worsening or requiring initiation
of medication. Height and weight were monitored
throughout the trial.
Physical and neurologic examinations, laboratory
assessment and electrocardiography were per-
formed, and vital signs were recorded; during the
baseline and the treatment periods and at study
completion, detailed records of adverse events
were documented.
During the follow-up, in all patients were per-
formed the following laboratorial examinations:
complete peripheral blood counts, urinary analysis
and measurement of blood creatinine, alanine
and aspartate aminotransferase levels, erythro-
cyte and leukocyte count, amylase, transaminase,
BUN.
Compared with baseline seizures frequency and
severity, the response to LEV treatment was classi-
fied as: seizures free (100% seizures control);
responders (>50% reduction) or marginal effect
(<50% reduction) in monthly seizures frequency.
The evaluation of the patients started after the
end of LEV titration. The efficacy of LEV therapy was
calculated by counting mean seizures frequency/
months; in particular, baseline period was 6 months
before LEV treatment; visit 6 months: mean seizures
frequency for the period ‘‘after the end of tritation’’
6 months; visit 12 months: mean seizures frequency
for the period 6—12 months.
Data of the patients are reported as mean  S.D.Results
No patients were lost during follow-up. All patients
remained on LEV therapy during the 12 months.Table 1 Effects of LEV on seizures frequency in the 21 pa
6 Months, newly
diagnosed patients
6 Mo
conv
patie
Seizures free 8 9
Responders 1 2
Marginal effect 0 1
Total 9 12Efficacy
Table 1 illustrates changes in seizures frequency at 6
months and 12 months of follow-up. During the first
6 months of the study 8 (30.1%) patients of the naı¨ve
group and 9 (42.8%) patients of second group
became seizure free.
At the end of follow-up, 9 (42.8%) ‘‘newly diag-
nosed patients’’ and 8 (30.1%) ‘‘converted patients’’
showed complete cessation of seizures. One patient
of the second group has been controlled for 6
months, but than relapsed and at the end, was
classified as ‘‘responder’’.
Tolerability
Adverse reactions occurred in 2 (9.5%) patients; in
these two patients drowsiness and irritability was
reported during the initial phase (2 weeks) of treat-
ment and than disappeared. No other important
adverse effects were observed during the therapy.
No findings of major clinical significance were noted
regarding the effects of study medication on labora-
tory test results, vital signs, electrocardiographic
recordings, physical and neurologic examinations,
and phychiatric and mental status.Discussion
Considering the spontaneous benign course of BECTS
a continuous treatment should be considered only in
subjects with frequent seizures. Moreover, patients
with frequent seizures and secondarily generalized
tonic-clonic seizures may need medication.1,4 LEV
hasprovenefficacy in this typeofepilepsyashasbeen
recently reported by Bello-Espinoza.22 Also our study
hasevaluated theefficacy and the safety of LEV in the
treatment of BECTS. This study suggests that LEV
monotherapy can be effective and very well toler-
ated in BECTS at the onset of disease as well as far
who failed other AEDs prior to LEV treatment. In
addition, this study shows a high retention rate of
LEV with all patients able to continue on LEV for 12
months. We treated two different types of patients:tients at 6 and 12 months
nths,
erted
nts
12 Months, newly
diagnosed patients
12 Months,
converted
patients
9 8
0 4
0 0
9 12
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response was significantly better in naive patients.
Recently, it has been underlined that this epi-
lepsy is a challenge in terminology and classifica-
tion,23 because BECTS is a heterogeneous condition
which includes a large spectrum of clinical fea-
tures;2,24,25 the atypical features could influence
the response to treatment.1,26
Although efficacy as measured by seizure fre-
quency is the principal outcome evaluated in stu-
dies, of great importance to the patient is the
change in quality of life made possible by a new
treatment. With regard to safety, LEV has been
reported to be a well-tolerated drug. Adverse reac-
tions, mainly represented by headache, infection,
somnolence and anorexia, have been reported, with
the incidence varying from 10 to 19%.27,28 Acute
psychosis has also been reported.29—32 In our experi-
ence, LEV has shown to be well tolerated, in fact,
only two patients reported transient somnolence
and irritability. Somnolence, dizziness, and head-
ache were three most frequent events also in the
large study performed by Tsai and Yen.18 We confirm
that these side effects are transient, in fact, pre-
vious studies showed that somnolence occurs pre-
dominantly during the initial phase of treatment
with LEV.16,18 Generally, adverse events of LEV were
typically of a non-serious nature, mild-to-moderate
in intensity, and only slightly more frequent than in
placebo-treated patients.33 This study provides
further support for the LEV safety: no discontinua-
tion due to adverse events was reported in our study,
confirming that LEV is a drug with a safe profile.
The small number of patients studied, as well as
the nature of this study and the short-term follow-
up, along with lack of randomization may not allow
us to make firm conclusions. However, our prelimin-
ary data suggest that LEV may be an acceptable
choice as monotherapy for BECTS.References
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